Press Room

May 28, 2015

ASCO Conference Data Show bioTheranostics’ Molecular Tests Significantly Impact Management of Metastatic Cancer Patients

Two Key Studies Support Role of CancerTYPE ID® Molecular Cancer Classifier & CancerTREATMENT NGS+ Biomarker Panels in Diagnosis & Management of Challenging Cancers

FOR IMMEDIATE RELEASE…May 28, 2015…CHICAGO…bioTheranostics, Inc., today announced that clinical study data disclosed at the American Society of Clinical Oncology (ASCO) annual meeting demonstrate that its CancerTYPE ID® molecular cancer classifier and CancerTREATMENT NGS+ biomarker tests provide actionable genomic information to support an accurate diagnosis and treatment of metastatic cancers. The ASCO meeting runs May 29–June 2, 2015, in Chicago.

A prospective, multicenter study that included 444 patients assessed the utility and impact of CancerTYPE ID in treatment decision-making in community clinical practice. The study demonstrated significant clinical utility of the test, changing treatment decisions in about half of patients. Clinical utility spanned a spectrum of diagnostic uncertainty for oncologists and pathologists, and helped narrow the differential diagnosis. Diagnosis of lung or colorectal cancer by CancerTYPE ID commonly informed the use of additional biomarker testing in the study. (Abstract #e15206)

A second retrospective study assessed the actionability of a combinatorial approach using the CancerTYPE ID assay followed by multi-platform biomarker profiling with CancerTREATMENT NGS+ in a large series of cases with unknown or uncertain origin that were identified as non-small cell lung cancer by CancerTYPE ID. Results demonstrate the clinical utility of a combinatorial approach using molecular diagnosis of tumor type and comprehensive multi-platform mutational profiling to enable precision medicine with tumor-specific and molecularly targeted treatment options. (Abstract #e19101)

Nicolas Barthelemy, president and CEO of bioTheranostics, said these study results provide additional evidence that the company’s suite of genomic tests delivers important diagnostic and therapeutic information for metastatic cancer patients at any stage across the continuum of cancer care. “There is a growing body of clinical evidence supporting the use of our industry leading CancerTYPE ID test to help classify tumor type and subtype, as well as the role of CancerTREATMENT NGS+ in identifying biomarkers linked to targeted treatments. These tests, part of our bioT3 Metastatic Cancer Solution, deliver the right information at the right time to help patients receive the right therapy, underscoring our commitment to personalized medicine for metastatic cancer patients.”

About bioT3 Metastatic Cancer Solution

bioT3 is a unique approach to metastatic cancer that combines the most validated gene expression panel to help achieve an accurate diagnosis, with a multiplatform solution that identifies the most relevant tumor-specific biomarkers to help guide treatment decisions. The bioT3 suite of tests includes:

  • CancerTYPE ID, a proprietary molecular test that aids in the determination of tumor type and subtype in metastatic cancer patients with unclear diagnosis. Twelve clinical studies involving more than 4,500 patient tumor samples have been published in peer-reviewed journals demonstrating its diagnostic accuracy and impact on patient outcomes.
  • CancerTreatment NGS+, a multi-platform approach that combines next-generation sequencing with a concise list of IHC and FISH tests aimed at identifying the most actionable biomarkers linked to targeted treatments.

About bioTheranostics

bioTheranostics, Inc., is a leader in helping physicians improve the care and management of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients. The company’s Breast Cancer IndexSM helps oncologists make difficult decisions about extended endocrine therapy for estrogen receptor-positive breast cancer patients. Its bioT3 Metastatic Cancer Solution combines accurate molecular diagnosis with comprehensive biomarker information that enables improved treatment for metastatic cancer patients. bioTheranostics, a bioMérieux company, is based in San Diego. For more information, visit www.biotheranostics.com.